Skip to main content
JW PHARMACEUTICAL logo

JW PHARMACEUTICAL — Investor Relations & Filings

Ticker · 001060 ISIN · KR7001060003 KO Manufacturing
Open in API
Filings indexed 310 across all filing types
Latest filing 2022-02-04 Major Shareholding Noti…
Country KR South Korea
Listing KO 001060

About JW PHARMACEUTICAL

https://www.jw-pharma.co.kr/pharma/en/m…

JW Pharmaceutical is a company focused on the research, development, and commercialization of pharmaceutical products. It provides a broad portfolio of therapeutic drugs, including specialty medicines and over-the-counter (OTC) solutions. Key product areas include nutritional infusions (Combiflex®, Winuf®), treatments for neutropenia (Neutrogin®), and cardiovascular medicines (Livalo®). Its consumer healthcare offerings feature the Hi-mom® brand of advanced wound care products. The company emphasizes innovation, advancing a pipeline of new drugs targeting oncology and immune diseases. This research is driven by proprietary technology platforms and includes candidates such as the gout treatment Epaminurad.

Recent filings

Filing Released Lang Actions
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) for JW Pharmaceutical. It details specific changes in share ownership for the major shareholder (JW Holdings) and various company executives/related parties due to a bonus share issuance. This type of filing is a standard regulatory disclosure regarding significant shareholding changes and ownership structure, which falls under the 'Major Shareholding Notification' category.
2022-02-04 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as a 'Section 16' equivalent in the US) where company insiders report changes in their shareholdings. Based on the provided categories, this falls under 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2022-02-04 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서), which is a standard regulatory filing in South Korea (DART system) used to disclose insider transactions or changes in shareholdings by company directors and executives. This corresponds to the 'Director's Dealing' category.
2022-02-04 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as a 'Section 16' equivalent in the US) where company insiders report their shareholdings and changes in ownership. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2022-02-04 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details changes in share ownership by major shareholders (JW Holdings and related parties) due to a bonus issue (무상증자). This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2022-02-04 Korean
벌금등의부과
Legal Proceedings Report Classification · 100% confidence The document is a regulatory disclosure from JW Pharmaceutical regarding the imposition of a fine (tax penalty) by the Seoul Regional Tax Office. It details the amount, the reason (tax audit), and the company's response. Since this relates to a regulatory/legal penalty and does not fit into specific categories like M&A, dividends, or share transactions, it is classified as a general regulatory filing.
2022-01-25 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.